Breaking News, Financial News

Financial Report: Valeant

Recent acquisitions recover generic losses

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Valeant 3Q Revenues: $2.1 billion (+33%) 3Q Earnings: $276.4 million (loss of $971.9 million in 3Q13) YTD Revenues: $5.9 billion (+61%) YTD Earnings: $378.1 million (loss of $988.6 million) Comments: Neuro & Other/Generics sales were $391.7 million, up 40% in the quarter. Dermatology sales were up 33% to $272.8 million. Consumer sales were $141.4 million, up 43%. Ophthalmology Rx sales were $117.8 million, up 57%. 2013 results include acquisition costs related to Bausch & Lomb and t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters